2026-01-24 - Analysis Report
**Thermo Fisher Scientific (TMO) Analysis Report**

**Company Overview**: Thermo Fisher Scientific is a leading provider of scientific instruments and laboratory products and services.

**Return Rate Comparison**

* Cumulative return of review stock (TMO): **110.96%**
* Cumulative return of comparison stock (S&P 500, VOO): **126.41%**
* Divergence: **-15.50** (-15.50%)
* Relative divergence: **30.40%**

The return rate of TMO is lower than the S&P 500, indicating a divergence of **15.50%**. The relative divergence of **30.40%** suggests that TMO is located at the lower end of the past data's fluctuation range.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 35.0% | 17.2% | 23.0% | 1.1 | 84.1B |
| 2017-2019  | 67.0% | 17.2% | 41.0% | 1.1 | 122.1B |
| 2018-2020  | 81.0% | 23.8% | 56.0% | 0.8 | 175.0B |
| 2019-2021  | 147.0% | 23.8% | 81.0% | 0.8 | 250.7B |
| 2020-2022  | 55.0% | 23.8% | 48.0% | 0.8 | 206.9B |
| 2021-2023  | -44.0% | 26.9% | -65.0% | 0.9 | 199.4B |
| 2022-2024  | -66.0% | 25.0% | -96.0% | 0.9 | 195.4B |
| 2023-2025  | -29.0% | 34.3% | -105.0% | 0.8 | 217.7B |

The Alpha, Beta analysis indicates a mix of high and low returns across different periods. The Alpha values (23.0%, 41.0%, 56.0%, 81.0%, 48.0%, -65.0%, -96.0%, -105.0%) suggest that TMO has outperformed the market in some periods but underperformed in others.

**Recent Stock Price Fluctuations**

* Close: **$625.98**
* Last-market: {'price': 625.98, 'previousClose': 639.45, 'change': -2.11}
* 5-day SMA: **$627.89**
* 20-day SMA: **$609.16**
* 60-day SMA: **$585.98**

The stock price has decreased by **-2.11%** over the last market day, indicating a sharp decline. The 20-day and 60-day moving averages suggest a downward trend.

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence, Expected_Return**

* Market Risk Indicator (MRI): **0.70** (0.9~1.0: High Investment Recommended, 0.7~0.9: Medium Investment, 0.4~0.7: Low Investment, <0.4: Very Risky)
* RSI: **63.47**
* PPO: **0.22**
* Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium (MRI 0.70)
Recent (20 days) relative divergence change: **0.70 (+)**: improving
7-day Rank change: **83 (+)**: rank up
7-day Dynamic Expected Return change: **94.20 (+)**: improving
Expected Return (%): **49.50%**, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

The Market Risk Indicator (MRI) is at **0.70**, indicating a medium-risk investment. The RSI and PPO values suggest a bearish trend. The Hybrid Signal is Buy, with a medium risk level.

**Recent News & Significant Events**

* [2026-01-23] Thermo Fisher Scientific's (NYSE:TMO) investors will be pleased with their decent 30% return over the last five years - Yahoo Finance
* [2026-01-23] Thermo Fisher (TMO) stock slides as investors square up ahead of Jan. 29 results - TechStock²
* [2026-01-23] Thermo Fisher Scientific Inc. $TMO Shares Acquired by UNIVEST FINANCIAL Corp - MarketBeat
* [2026-01-23] Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings? - Nasdaq
* [2026-01-23] Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings? - Zacks Investment Research
* [2026-01-22] Thermo Fisher’s AI Lab Push And Leadership Shift Might Change The Case For Investing In TMO - simplywall.st

The recent news suggests a mixed sentiment, with some reports indicating a decent return and others noting a sharp decline.

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.54 (~Buy)
- Opinions: 23
- Target Price (avg/high/low): 652.61 / 750.00 / 575.00

The analyst consensus is Buy, with a mean rating of **1.54** and **23** opinions.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|----|---------|
| 2025-10-31 | 4.28 | 11.12 B$ |
| 2025-08-01 | 4.28 | 10.86 B$ |
| 2025-05-02 | 3.99 | 10.36 B$ |
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2025-10-31 | 4.26 | 10.60 B$ |

The recent earnings analysis indicates a mix of high and low EPS and revenue values across different periods.

**Financial Information**

### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.12B | 41.21% |
| 2025-06-30 | $10.85B | 40.61% |
| 2025-03-31 | $10.36B | 40.86% |
| 2024-12-31 | $11.39B | 42.32% |
| 2024-09-30 | $10.60B | 40.84% |

### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.02B | 3.17% |
| 2025-06-30 | $50.51B | 3.20% |
| 2025-03-31 | $49.39B | 3.05% |
| 2024-12-31 | $49.59B | 3.69% |
| 2024-09-30 | $48.99B | 3.33% |

The financial information indicates a mix of high and low revenue and profit margins across different periods. The equity and ROE values suggest a medium-risk investment.

**Comprehensive Analysis (Summary of previous items)**

* Return rate comparison: TMO has a lower cumulative return than the S&P 500.
* Alpha, Beta analysis: TMO has a mix of high and low returns across different periods.
* Recent stock price fluctuations: The stock price has decreased by **-2.11%** over the last market day.
* RSI, PPO index indicators and Delta_Previous_Relative_Divergence, Expected_Return: The Market Risk Indicator (MRI) is at **0.70**, indicating a medium-risk investment.
* Recent news and significant events: The news suggests a mixed sentiment.
* Analyst opinions: The analyst consensus is Buy, with a mean rating of **1.54** and **23** opinions.
* Recent earnings analysis: The earnings analysis indicates a mix of high and low EPS and revenue values across different periods.
* Financial information: The financial information indicates a mix of high and low revenue and profit margins across different periods.

Overall, the comprehensive analysis suggests a medium-risk investment with a mix of high and low returns across different periods.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.